← Leaderboards
Lori A Hazlehurst
H. Lee Moffitt Cancer Ctr & Res Inst
$3,535,294
Attributed
$4,098,134
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $563K · FY2007–19$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,098,134 · 6
By mechanism
R01$3,097,460 · 2
R21$400,655 · 1
R43$375,019 · 2
R41$225,000 · 1
Top collaborators
- Mark L Mclaughlin3 shared
- Conor C Lynch2 shared
- Priyesh Jain1 shared
- Rajesh R Nair1 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Daniel Abate-Daga$2,954,893
- Conor C Lynch$9,082,731
- David Basanta Gutierrez$3,082,070
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaCellsCell DeathResistanceSpecimenRegulationIn VitroMediatingTumorIn Vivo ModelExtracellular MatrixBinding (Molecular Function)Signal TransductionCell SurvivalResponsePeptidesPharmaceutical PreparationsPreventHomingIn VivoClinical TrialsMsx1 GeneKillingsBone Marrow
Grant awards (16)
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma$319,834
R01 · FY2019 · CA · contact PI
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma$330,412
R01 · FY2018 · CA · contact PI
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma$331,081
R01 · FY2017 · CA · contact PI
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma$333,497
R01 · FY2016 · CA · contact PI
Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma$180,762
R21 · FY2016 · CA
Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma$343,122
R01 · FY2015 · CA · contact PI
Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma$219,893
R21 · FY2015 · CA
Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp$225,000
R41 · FY2014 · CA
Targeting CD44 in the bone marrow microenvironment of MM$218,817
R43 · FY2012 · CA
Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the$156,202
R43 · FY2012 · CA
Role of Bim in mediating CAM-DR in hematopoietic tumors$275,344
R01 · FY2011 · CA · contact PI
Role of Bim in mediating CAM-DR in hematopoietic tumors$283,860
R01 · FY2010 · CA · contact PI
Role of Bim in mediating CAM-DR in hematopoietic tumors$255,442
R01 · FY2009 · CA · contact PI
Role of Bim in mediating CAM-DR in hematopoietic tumors$283,860
R01 · FY2008 · CA · contact PI
Role of Bim in mediating CAM-DR in hematopoietic tumors$62,278
R01 · FY2008 · CA · contact PI
Role of Bim in mediating CAM-DR in hematopoietic tumors$278,730
R01 · FY2007 · CA · contact PI